Clinical Trial

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-12-13; most recent amendment 2025-12-14.
Status change: Not Yet Recruiting → Recruiting 2024-09-10
Trial Details
NCT Number NCT06182969
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: Suzhou Yasheng Pharmaceutical Co., Ltd.
Conditions SLE
Enrollment 40 participants
Start Date 2024-08-09
Primary Completion 2026-04 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-16